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Abstract 
Background: Alterations in one-carbon metabolism (OCM) have been observed in patients with schizophrenia 
(SZ), but a comprehensive study of OCM has not yet been conducted. A carbon atom is transferred from l-serine to 
methionine during OCM, but the relationship between l-serine and methionine in SZ is not yet known. We investi-
gated the relationship between l-serine and methionine to obtain a comprehensive understanding of OCM in SZ.
Methods: We recruited forty-five patients with SZ and thirty normal controls (NC). Whole blood, plasma, and DNA 
specimens were obtained from all participants. Plasma l-serine, d-serine, glycine, methionine, and total homocyst-
eine levels were measured using high-performance liquid chromatography. Plasma vitamin B12 and total folate were 
measured using a chemiluminescent protein-binding immunoassay. Clinical symptoms were estimated using the 
positive and negative syndrome scale (PANSS). The methylenetetrahydrofolate reductase (MTHFR) C667T genotype 
and A298C genotype, which are involved in MTHFR activity, were determined using the TaqMan genotyping assay 
system.
Results: Analysis of variance was used to confirm that the SZ cohort has higher plasma homocysteine levels and 
lower plasma folate levels than the NC group. Multi-regression analysis revealed a relationship between l-serine and 
methionine in the NC group but not in the SZ group. The MTHFR genotype did not affect the relationship between 
l-serine and methionine in each group. The total PANSS score was significantly related to d-serine and folate levels and 
to age. Positive PANSS scores were significantly related to both glycine and sex. In addition, both glycine and d-serine 
were significantly correlated with negative PANSS scores.
Conclusions: We found impairment of the relationship between l-serine and methionine in SZ. Clinical symptoms 
of SZ were partially correlated with the OCM components. These findings contributed to our understanding of OCM 
alteration in SZ and may explain why the alteration occurs.
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Background
One-carbon metabolism (OCM) alteration has been 
observed in patients with schizophrenia (SZ) [1–4]. 
OCM involves methionine cycles and folate cycles to 
generate diverse outputs such as substrates for methyla-
tion reactions and the maintenance of redox status [5]. 
The folate cycle results in the transfer of the methyl-
ene group (one carbon atom) from l-serine by catalysis 
of serine hydroxymethyltransferase to the methionine 
cycle. l-serine is converted into glycine by donating 
its methylene group to the methionine cycle, which is 
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a part of OCM. Methionine is synthesized from homo-
cysteine (Hcy) using a carbon atom that is obtained from 
the folate cycle (Fig.  1) [5]. Some components of OCM 
are altered in patients with SZ. Elevated Hcy [4, 6–10] 
and low folate [11, 12] and vitamin B12 (VB12) levels 
[13] have been reported in patients with SZ; however, 
the relationship between each alteration is unknown. 
For example, the peripheral serine level is considered 
to be significantly higher in SZ patients than in nor-
mal controls (NC), especially in male controls [14, 15]. 
Yet, l-serine’s relationship with OCM has not been well 
investigated. The carbon atom that belongs to OCM is 
exchanged between l-serine and methionine. Therefore, 
we explored the relationship between methionine and 
l-serine to obtain a comprehensive understanding of the 









Fig. 1 The carbon atom of one-carbon metabolism is exchanged between l-serine and methionine. The folate cycle obtains the methylene group 
(one carbon atom) from l-serine via the catalysis of serine hydroxymethyltransferase (SHMT) and subsequently donates the carbon to methionine 
synthesis. l-serine becomes glycine by offering the methylene group to methionine synthesis. Methionine is synthesized from homocysteine (Hcy) 
using a folate cycle-derived carbon atom. MTHFR methylenetetrahydrofolate reductase; MTR 5-methyltetrahydrofolate-homocysteine methyltrans-
ferase
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Methods
Participants
We recruited forty-five SZ and thirty NC patients 
between 2010 and 2013. All participants were treated at 
one of the three hospitals: Dokkyo Medical University 
Hospital, Mori Hospital, or Shimotsuga General Hos-
pital. Demographic data of the participants are shown 
in Table  1. All SZ patients were in a stable state. Par-
ticipants with severe complications that could be con-
firmed by physical examination and laboratory testing 
for liver function, renal function, lipid metabolism and 
glucose metabolism, were excluded. The results of physi-
cal examinations and laboratory testing of patients were 
obtained from medical records by research psychiatrists 
(YT, YO, KF, TW, HO, TS, AA, KA, and KS). NC partici-
pants were interviewed by a research psychiatrist (KA) to 
obtain detailed medical histories and confirm that they 
were not suffering from mental illness or severe physi-
cal disease. Psychiatric histories were taken from each 
medical record by a research psychiatrist (KA). Two 
independent psychiatrists used the American Psychiatric 
Association’s Diagnostic and Statistical Manual of Mental 
Disorders [16] criteria to assess all patients (YO and KA). 
The positive and negative syndrome scale (PANSS) [17] 
was used to measure clinical symptoms in all patients by 
a research psychiatrist who was trained and experienced 
in the rating scales (KA). After fully explaining the study 
procedures, we obtained written, informed consent from 
all participants. The study was approved by the ethics 
committee of the Dokkyo Medical University School of 
Medicine.
Plasma l‑serine, d‑serine, glycine, methionine, and total 
homocysteine analysis
Before noon, 8  mL whole blood samples were drawn 
from each participant and placed into BD Vacutainer® 
CPT™ cell preparation tubes containing sodium hepa-
rin (Becton, Dickinson Co., Plainfield, NJ, USA). We fol-
lowed the manufacturer’s instructions to separate plasma 
from the whole blood sample, which was then stored at 
−80 °C.
The samples for high-performance liquid chromatogra-
phy were prepared as previously described [18]. Briefly, 
150  μL of H2O and 10  μL of 40  % (w/v) trichloroacetic 
acid were added to 50  μL of plasma and mixed by vor-
texing. After centrifugation at 15,000  rpm for 10  min-
utes at 4 °C, 150 μL of the supernatant was removed and 
added to 130 μL of H2O, 100 μL of 200 mM borate buffer 
(pH 8.5), and 20 μL of 1 M NaOH before being vortex-
mixed. Fluorescent derivatization was conducted by add-
ing 40 μL of 50 mM borate buffer (pH 8.5) and 50 μL of 
10  mM 4-fluoro-7-nitro-benzoxadiazole (NBD-F) solu-
tion to 20 μL of the above-described solution. The mix-
ture was incubated at 60  °C for 5 minutes. The reaction 
was stopped by adding 890 μL of 2 % trifluoroacetic acid 
(TFA).
Separation and fluorometric detection of NBD-gly-
cine and NBD-methionine were conducted according 
to a previous study [19], except that TSKgel ODS-
80Ts QA (250  ×  4.6  mm, i.d., 5  μm, Tosoh Corpora-
tion, Tokyo, Japan) was used as an ODS column, 
and the elution solvent and program were modified 
accordingly.
Separation and fluorometric detection of NBD-d- 
and -l-serine were performed according to the meth-
ods of a previous study [18], except that InertSustain 
(250  ×  4.6  mm, i.d., 5  μm, GL Sciences Inc., Tokyo, 
Japan) and Sumichiral OA-3200 (250  ×  4.6  mm, i.d., 
5  μm, Sumika Analytical Center, Osaka, Japan) were 
used as a reverse-phase octyl silica column and a Pirkle-
type chiral column, respectively. Additionally, separa-
tion on the octyl silica column and the chiral column 
was conducted using mobile phases of 1 % methanol and 
0.01 % TFA in 15 % acetonitrile (0.8 mL/min) and 1 mM 
citrate in methanol: acetonitrile (95:5; 1.0  mL/min), 
respectively.
Hcy was labeled with 4-fluoro-7-sulfamoylbenzo-
furazan and detected using a fluorescence detector, 
according to the method of a previous study [20]. The 
Table 1 Demographics of participants
Positive: subscale of positive syndrome scale in PANSS
Negative: subscale of negative syndrome scale in PANSS




Number of participant 45 30
Sex Male: 27 Male: 18
Age 50.6 ± 12.6 45.5 ± 13.0
Number of smoker 15 8
Duration of illness (years), 
mean ± SD
27.3 ± 12.8
CP equivalent dose (mg/day), 
mean ± SD
667.58 ± 635.28
l-serine (μM), mean ± SD 91.2 ± 21.1 85.6 ± 22.4
d-serine (μM), mean ± SD 1.50 ± 0.42 1.37 ± 0.45
Glycine (μM), mean ± SD 194.9 ± 64.0 176.5 ± 49.6
Vitamin B12 (pg/mL), mean ± SD 348.7 ± 132.6 309.5 ± 154.0
Folate (ng/mL), mean ± SD* 4.4 ± 1.7 5.7 ± 2.7
Homocysteine (μM), mean ± SD** 13.4 ± 8.3 9.1 ± 2.6
Methionine (μM), mean ± SD 13.1 ± 5.3 11.2 ± 7.1
PANSS score, mean ± SD 72.7 ± 17.9
Positive, mean ± SD 14.4 ± 5.4
Negative, mean ± SD 23.0 ± 6.0
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chemicals were purchased from Sigma-Aldrich Japan 
(Tokyo, Japan), except as indicated above.
Plasma VB12 and total folate analysis
VB12 and total folate were measured using a chemilumi-
nescent protein-binding immunoassay (Beckman Coul-
ter, CA, USA). All assays were performed according to 
the manufacturers’ instructions.
Genotyping
The MTHFR C677T genotype (rs 1801133) and A1298C 
(rs 1801131) genotype, in which minor alleles elevate 
the Hcy concentration [21], were determined using a 
commercially available TaqMan single nucleotide poly-
morphism Genotyping Assay Kit (Applied Biosystems, 
Life Technologies, CA, USA) and a stratagene Mx3000P 
QPCR system (Agilent Technologies, CA, USA), accord-
ing to the protocol recommended by the manufac-
turer. The assay IDs were C_1202883 and C_850486, 
respectively.
Statistical analysis
We used analysis of covariance to compare the demo-
graphics data and measurement results (plasma con-
centration of l-serine, d-serine, glycine, VB12, folate, 
Hcy, and methionine) of SZ and NC. Allelic and geno-
typic frequencies of the MTHFR C677T and A1298C 
polymorphisms in SZ and NC, respectively, were com-
pared using the χ2 test. Multiple linear regression analy-
sis, with both the forced entry model and the backward 
elimination model, was used to examine the relation-
ship between the plasma methionine level and plasma 
amino acids (l-serine, d-serine, and glycine), Hcy, VB12, 
and folate concentrations in both SZ and NC. In the 
NC group, l-serine, d-serine, glycine, Hcy, VB12 and 
folate levels, age, sex, and smoking status were consid-
ered independent variables. In the SZ group, l-serine, 
d-serine, glycine, Hcy, VB12 and folate levels, age, sex, 
antipsychotic dose (chlorpromazine-equivalent dose), 
duration of disease, and smoking status were considered 
as independent variables. Furthermore, the relationship 
between the PANSS score (total score, positive score, 
and negative score) and data (demographic and meas-
ured) were examined in SZ patients using multiple lin-
ear regression analysis with both the forced entry model 
and the backward elimination model. Multicollinearity 
in each model was estimated using a variance inflation 
factor. A variance inflation factor of greater than five is 
generally considered evidence of multicollinearity [22]. 
All statistical analyses were performed using the statisti-
cal package PASW, Version 18.0 (SPSS Japan Inc., Tokyo, 
Japan). Statistical significance was defined as a p-value of 
less than 0.05.
Results
The mean Hcy level was significantly higher in the 
SZ group than in the NC group (F  =  7.58; p  =  0.007; 
Table 1), whereas the mean folate level was significantly 
lower in the SZ group than in the NC group (F =  6.23; 
p  =  0.015; Table  1). With regard to genotype, no sig-
nificant differences were found between the two groups 
(rs 180131: χ2  =  3.26, p  =  0.20; rs 180133: χ2  =  0.97, 
p = 0.62; Table 2).
Multiple regression analysis was performed to deter-
mine the relationship between methionine and other 
factors. In the NC group, multiple regression analy-
sis indicated no reliance in the forced entry model 
[adjusted R2  =  0.16, F (9, 20)  =  1.51; p  =  0.21]; how-
ever, reliance was obtained in the backward elimination 
model (adjusted R2 = 0.41, F (2, 27) = 7.76; p = 0.001). 
In this model, l-serine level (t =  2.8; β =  0.43 ±  0.15; 
p =  0.008), age (t =  2.62; β =  0.53 ±  0.15; p =  0.001), 
and sex (t = −2.15; β = −0.33 ± 0.15; p = 0.041) were 
significantly correlated with the methionine level. In 
the SZ group, no factor was associated with the methio-
nine level in both the forced entry model and the back-
ward elimination model (Table  3) (forced entry model: 
adjusted R2 = 0.12, F (13, 31) = 0.67, p = 0.78; backward 
elimination model: adjusted R2 = 0.06, F (2, 42) = 3.33, 
p = 0.76).
The factors that related to the PANSS score were deter-
mined using multiple regression analysis in SZ patients. 
The forced entry model of the total PANSS score indi-
cated no reliance [adjusted R2 = 0.26, F (13, 31) = 1.94; 
p = 0.077]; however, the backward elimination model was 
reliant [adjusted R2 = 0.32, F (5, 39) = 3.92; p = 0.005]. 
In this model, levels of folate (t = 2.18; β = 0.35 ± 0.16; 
p  =  0.037), d-serine (t  =  2.68; β  =  0.38  ±  0.16; 
p = 0.012), and age (t = 0.37; β = 0.54 ± 0.15; p < 0.001) 
were indicated as factors that were related to the total 
PANSS score. No reliance was observed in the forced 
entry model for either a positive PANSS score [adjusted 
R2  =  0.33, F (13, 31)  =  2.32; p  =  0.035] or a negative 
PANSS score [adjusted R2  =  0.17, F (13, 31)  =  1.54; 
Tabel  2 Allele frequency and  genotyping of  the MTHFR 
SNPs in participants
MTHFR methylenetetrahydrofolate reductase, HWE Hardy–Weinberg equilibrium
Allele Genotype p value for HWE
rs1801131
 Schizophrenia A: 76, C: 14 AA: 34, AC: 8, CC: 3 0.20
 Control A: 51, C: 9 AA: 21, AC: 9, CC: 0
rs1801133
 Schizophrenia C: 52, T: 38 CC: 17, CT: 18, TT: 10 0.62
 Control C: 38, T: 22 CC: 12, CT: 14, TT: 4
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p =  0.17]. In contrast, the backward elimination model 
was reliable in both positive [adjusted R2  =  0.30, F 
(6, 38)  =  9.04; p  =  0.001] and negative PANSS scores 
[adjusted R2 =  0.17, F (6, 38) =  3.58; p =  0.024]. Posi-
tive PANSS scores were significantly related to both the 
glycine level (t = 5.50; β = 0.47 ± 0.13; p = 0.001) and 
sex (t = −3.69; β = −0.71 ± 0.19; p < 0.001). In addition, 
both glycine (t = −3.16; β = −0.61 ±  0.16; p =  0.004) 
and d-serine (t = 2.44; β = 0.47 ± 0.19; p = 0.021) were 
significantly correlated with negative PANSS scores 
(Table 4).
Discussion
In this study, we found a relationship between methio-
nine and l-serine in the NC group, but this relationship 
did not exist in the SZ group. Increased plasma Hcy lev-
els and decreased folate levels were observed in the SZ 
group. The PANSS scores of clinical symptoms correlated 
with folate, d-serine, and glycine levels.
A number of studies have reported OCM alteration 
in SZ [1–4]. In the OCM cycle, methionine is synthe-
sized by a chemical reaction between Hcy and a carbon 
atom provided by l-serine. Elevated peripheral l-serine 
levels have also been reported in SZ [14, 15]. Although 
l-serine and methionine exchange a carbon atom in 
OCM, the relationship between l-serine and methionine 
in OCM has not been investigated in SZ. For this rea-
son, we investigated the relationship between l-serine 
and methionine in schizophrenia. In this investigation, 
we confirmed the relationship between methionine and 
l-serine in the NC group; however, no relationship was 
identified in SZ. This result indicates an impairment of 
the relationship between l-serine and methionine in SZ 
and that the impairment may induce high peripheral Hcy 
levels and high peripheral l-serine levels in SZ. In agree-
ment with previous studies [4, 6–10], we confirmed that 
the peripheral Hcy level was higher in the SZ group than 
in the NC group. High peripheral l-serine levels in SZ 
Table 3 Relationship between methionine and other factors in patients with schizophrenia and normal controls: multiple 
regression analysis
β  standardised partial regression coefficient, VIF variance inflation factor, CP chlorpromazine, SD standard deviation
Forced entry model Backward elimination model
β ± SD p value VIF β ± SD p value VIF
Normal control
 Sex −0.33 ± 0.23 0.17 1.90 −0.33 ± 0.15 0.04 1.18
 Age 0.55 ± 0.20 0.01 1.51 0.53 ± 0.15 <0.001 1.09
 Smoking status −0.05 ± 0.21 0.92 1.55
 Vitamin B12 −0.11 ± 0.28 0.70 2.76
 Folate −0.08 ± 0.24 0.75 2.06
 Homocysteine −0.08 ± 0.21 0.71 1.55
 l-serine 0.40 ± 0.28 0.17 2.79 0.43 ± 0.15 0.008 1.13
 d-serine −0.03 ± 0.29 0.92 3.06
 Glycine 0.02 ± 0.28 0.94 1.91
 Genotype131 −0.03 ± 0.19 0.89 1.25
 Genotype133 0.08 ± 0.25 0.75 2.37
Patients with schizophrenia
 Sex −0.06 ± 0.28 0.83 2.71
 Age 0.21 ± 0.37 0.57 4.76
 Duration of illness −0.02 ± 0.32 0.95 3.32
 Smoking status 0.12 ± 0.25 0.63 2.19
 CP equivalent dose −0.01 ± 0.28 0.95 1.53
 Vitamin B12 0.06 ± 0.22 0.74 1.29
 Folate −0.11 ± 0.21 0.61 1.64
 Homocysteine −0.29 ± 0.23 0.23 1.93 −0.35 ± 0.16 0.14 1.18
 l-serine 0.15 ± 0.26 0.55 2.31
 d-serine −0.13 ± 0.27 0.63 2.58
 Glycine 0.10 ± 0.26 0.67 2.05
 Genotype131 0.32 ± 0.24 0.20 2.07 0.35 ± 0.16 0.14 1.36
 Genotype133 0.21 ± 0.28 0.46 2.77 0.27 ± 0.18 0.14 1.18
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Table 4 Relationship between PANSS score and other factors in patients with schizophrenia: multiple regression analysis
β standardised partial regression coefficient, VIF variance inflation factor
Forced entry model Backward elimination model
β ± SD p value VIF β ± SD p value VIF
PANSS score
 Sex −0.13 ± 0.22 0.57 2.42
 Age −0.62 ± 0.32 0.06 5.04 −0.54 ± 0.15 <0.001 1.16
 Smoking status −0.15 ± 0.20 0.44 1.91
 Duration of illness 0.16 ± 0.25 0.53 3.22
 CP equivalent dose 0.11 ± 0.18 0.52 1.38
 Vitamin B12 0.05 ± 0.15 0.76 1.31
 Folate 0.30 ± 0.19 0.12 1.73 0.35 ± 0.16 0.04 1.41
 Homocysteine 0.38 ± 0.21 0.09 2.31 0.27 ± 0.16 0.10 1.43
 l-serine 0.00 ± 0.00 1.00 3.26
 d-serine 0.43 ± 0.25 0.10 3.08 0.38 ± 0.14 0.01 1.07
 Glycine −0.13 ± 0.20 0.53 2.13
 Methionine 0.34 ± 0.16 0.05 1.35 0.29 ± 0.15 0.07 1.29
 Genotype131 −0.29 ± 0.20 0.16 1.96 −0.25 ± 0.15 0.10 1.18
 Genotype133 −0.14 ± 0.23 0.55 2.61
Positive PANSS score
 Sex −0.03 ± 0.21 0.89 2.42 −0.71 ± 0.19 <0.001 2.21
 Age −0.68 ± 0.30 0.04 5.04
 Smoking status −0.04 ± 0.18 0.82 1.91
 Duration of illness 0.25 ± 0.24 0.32 3.22 0.31 ± 0.19 0.11 2.07
 CP equivalent dose 0.12 ± 0.12 0.45 1.38
 Vitamin B12 0.14 ± 0.16 0.38 1.31
 Folate 0.32 ± 0.18 0.08 1.73 0.25 ± 0.14 0.08 1.12
 Homocysteine 0.31 ± 0.20 0.15 2.31
 l-serine 0.07 ± 0.24 0.77 3.26
 d-serine 0.22 ± 0.24 0.36 3.08
 Glycine 0.31 ± 0.20 0.13 2.13 0.47 ± 0.13 <0.001 1.06
 Methionine 0.26 ± 0.16 0.11 1.35 0.19 ± 0.15 0.20 1.25
 Genotype131 −0.32 ± 0.19 0.11 1.96 −0.23 ± 0.14 0.11 1.16
 Genotype133 −0.06 ± 0.22 0.78 2.61
Negative PANSS score
 Sex −0.05 ± 0.23 0.82 2.42
 Age −0.42 ± 0.34 0.23 5.04 −0.25 ± 0.15 0.11 1.07
 Smoking status −0.18 ± 0.21 0.38 1.91 −0.27 ± 0.16 0.11 1.27
 Duration of illness 0.15 ± 0.27 0.58 3.22
 CP equivalent dose 0.12 ± 0.24 0.50 1.38
 Vitamin B12 0.05 ± 0.18 0.79 1.31
 Folate 0.14 ± 0.20 0.49 1.73
 Homocysteine 0.37 ± 0.23 0.12 2.31 0.24 ± 0.18 0.19 1.48
 l-serine 0.14 ± 0.27 0.61 3.26
 d-serine 0.30 ± 0.26 0.27 3.08 0.47 ± 0.19 0.02 1.73
 Glycine −0.53 ± 0.22 0.02 2.13 −0.61 ± 0.20 0.004 1.76
 Methionine 0.28 ± 0.17 0.12 1.35
 Genotype131 −0.37 ± 0.21 0.09 1.96 −0.16 ± 0.15 0.30 1.10
 Genotype133 −0.31 ± 0.24 0.22 2.61
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were also reported [14, 15] but have not been confirmed 
because this observation was made in a small number 
of participants. To date, the reason why the peripheral 
Hcy level and l-serine level is higher in SZ than in NC 
remains unknown.
Low folate levels [11] and low VB12 levels [12, 13] have 
also been reported in SZ. We confirmed low folate but 
not low VB12 levels in the present study. Folate carries 
a carbon atom from l-serine to methionine, which is 
synthesized from Hcy (Fig.  1). MTHFR plays an impor-
tant role in this pathway because MTHFR catalyzes the 
conversion of 5,10-methylenetetrahydrofolate to 5-meth-
yltetrahydrofolate, a co-substrate for Hcy remethylation 
to methionine. Some allelic variants change enzymatic 
activity. For example, the MTHFR C677T and A1298C 
genotypes reduce the activity of MTHFR and finally ele-
vate the peripheral Hcy level [23]. These allelic variants 
have been indicated as risk factors of SZ [24–31]. There-
fore, the disruption of the relationship between l-serine 
and methionine could be elucidated by the frequency of 
MTHFR allele variants. Nevertheless, we found no rela-
tionship between the allele variant frequency and the Hcy 
level (data not shown), even though a higher level of Hcy 
in SZ was observed. Because the effect size of MTHFR 
allelic variants for the plasma Hcy levels was relatively 
low (odds ratio: 1.14) [9], we cannot conclusively indi-
cate the allelic variant effect as a reason for impairment 
of the relationship between l-serine and methionine. A 
study with an increased number of participants would be 
needed to study this further.
Although we found no effect of the MTHFR allele vari-
ant, the relationship between l-serine and methionine 
was altered in SZ, suggesting another reason for this 
alteration. For example, the low supply or high consump-
tion of folate could be a contributing factor to the disrup-
tion of plasma folate levels, which were lower in the SZ 
group than in the NC group. Further studies and confir-
mation of these findings are necessary to determine the 
reason for our finding of an altered relationship between 
l-serine and methionine in SZ. It is worth noting; how-
ever, that MTHFR allelic variants may not be the only 
cause of OCM alteration in SZ.
With regard to the relationship between OCM and 
clinical symptoms of SZ, significant negative relation-
ships between the serum folate levels and the total 
PANSS scores and the negative PANSS symptom score 
in SZ [32] have been reported. Additionally, there was a 
positive relationship between the serum Hcy levels and 
the total PANSS scores [32]; however, these relationships 
were not confirmed in our results. We found a positive 
relationship between plasma folate and total PANSS 
score. The Hcy levels did not correlate with clinical 
symptoms in our study. No firm conclusion can be made 
concerning a relationship between clinical symptoms and 
peripheral levels of folate or Hcy in SZ.
Calcia et  al., found that d-serine levels were inversely 
correlated with the total Brief Psychiatric Rating Scale 
(BPRS) score and with the BPRS score for negative symp-
toms, but not with the BPRS score for positive symptoms 
[33]. In contrast, Hone et al., reported that d-serine serum 
levels were not associated with the PANSS or Scale for the 
Assessment of Negative Symptoms (SANS) total and sub-
scales scores [34]. They also showed serum glycine levels 
to be negatively associated with the intensity of negative 
symptoms assessed by the PANSS negative subscale [35]. 
In our study, the plasma d-serine concentration was posi-
tively correlated with both the total PANSS score and the 
positive PANSS score. We also found the plasma glycine 
levels to be negatively correlated with a negative PANSS 
score and positively correlated with a positive PANSS 
score. These findings were statistically significant. Further 
evaluation of the correlation between clinical symptoms 
and peripheral d-serine or glycine levels is necessary to 
explain the discrepancies between studies. Because both 
d-serine and glycine are considered adjunctive agents 
[36–38], alteration of both of these amino acids is likely 
to be found in SZ. Nevertheless, no firm conclusion has 
been reached concerning the relationship between clinical 
symptoms and peripheral levels of d-serine or glycine.
One limitation of our study was the relatively low num-
ber of participants. This resulted in a low allele variant 
effect on MTHFR enzyme activity, making it difficult 
to evaluate the effect of the allelic variant in our find-
ings. The other limitation was that all SZ patients were 
receiving antipsychotic medication, which could have 
impacted our results. Even though no statistical effect 
was observed, we cannot completely rule out the effect 
of antipsychotic medications on OCM. Until now, the 
effect of antipsychotics medications on OCM was mainly 
focused on the relationship between antipsychotics and 
Hcy. However, the results are inconsistent. Nishi et  al., 
did not find a relationship between antipsychotic dose 
and plasma Hcy level [9]. In contrast, Misaki et al., found 
an increase of serum Hcy level by second-generation 
antipsychotic medication [39]. They did not examine the 
peripheral methionine level. The inconsistencies make it 
difficult to determine the effect that antipsychotic medi-
cation may have on OCM, which should be examined in 
future studies. A larger sample size would allow patients 
to be divided into subgroups by medication to gain a bet-
ter understanding of the effect of antipsychotic medica-
tion and provide results applicable to clinical situations. 
Furthermore, the cross-sectional nature of this study 
design did not allow a causal relationship to be deter-
mined between severity of symptoms and levels of folate, 
d-serine, and glycine.
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Conclusions
In conclusion, we found no relationship between l-ser-
ine and methionine in SZ. It is our hope that the findings 
of this study will contribute to a comprehensive under-
standing of OCM alteration in SZ. Determining the cause 
of OCM alterations could lead to investigations of new 
therapeutic targets in future studies.
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